$6.63
-0.28-3.99%
Ult. Agg.: Nov 17, 9:55 AM

The average analyst price target for MapLight Therapeutics is $32.45, 389.8% above the current price. Of 12 analysts, 10 rate it Buy and 2 Hold. Targets range from $13 to $46. The latest change came on Oct 6, 2026, when Guggenheim initiated coverage of MapLight Therapeutics with a Neutral rating.
Price Target Range — 4 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months